{
    "name": "trimagnesium citrate anhydrous",
    "comment": "OTC",
    "other_names": [
        "Magnitria"
    ],
    "classes": [
        "Electrolytes"
    ],
    "source": "https://reference.medscape.com/drug/mangnitria-trimagnesium-citrate-anhydrous-999877",
    "pregnancy": {
        "common": [
            "Pregnancy Category: B; crosses placenta, physician should guide dosage for pregnant women",
            "Lactation: Excreted in human breast milk; concentrations remain constant during the first year of lactation; effects of prolonged increments in magnesium are not known",
            "Pregnant or breastfeeding patients should seek advice of health professional before using OTC drugs"
        ],
        "specific": []
    },
    "lactation": {
        "common": [
            "Lactation: Excreted in human breast milk; concentrations remain constant during the first year of lactation; effects of prolonged increments in magnesium are not known"
        ]
    },
    "warnings": {
        "black_box_warning": {
            "common": [],
            "specific": []
        },
        "contraindicators": {
            "common": [
                "Known hypersensitivity to proton pump inhibitors",
                "GI obstructions",
                "Hypermagnesemia"
            ],
            "specific": []
        },
        "cautions": {
            "common": [
                "Kidney dysfunction",
                "Patients who experience a sudden change in bowel habits",
                "Coadministration with calcium channel blockers; magnesium may enhance the hypotensive effect of the calcium channel blockers",
                "May enhance neuromuscular-blocking effect of neuromuscular-blocking agents",
                "Avoid concomitant use of calcium polystyrene sulfonate",
                "High fat content of food decreases magnesium absorption"
            ],
            "specific": []
        }
    },
    "interactions": [
        {
            "classification_type": "Serious",
            "interaction_with": "baloxavir marboxil",
            "description": {
                "common": "trimagnesium citrate anhydrous will decrease the level or effect of baloxavir marboxil by  cation binding in GI tract. Avoid or Use Alternate Drug. Baloxavir may bind to polyvalent cations resulting in decreased absorption. Studies in monkeys showed concurrent use with calcium, aluminum, or iron caused significantly decreased plasma levels. Human studies not conducted."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "alendronate",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of alendronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amikacin",
            "description": {
                "common": "amikacin, trimagnesium citrate anhydrous.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of aminoglycosides with magnesium may increase risk of neuromuscular weakness and paralysis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "amlodipine",
            "description": {
                "common": "trimagnesium citrate anhydrous, amlodipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ciprofloxacin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of ciprofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "demeclocycline",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of demeclocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "digoxin",
            "description": {
                "common": "digoxin decreases effects of trimagnesium citrate anhydrous by increasing renal clearance. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "diltiazem",
            "description": {
                "common": "trimagnesium citrate anhydrous, diltiazem.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "doxycycline",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of doxycycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "felodipine",
            "description": {
                "common": "trimagnesium citrate anhydrous, felodipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gemifloxacin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of gemifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "gentamicin",
            "description": {
                "common": "gentamicin, trimagnesium citrate anhydrous.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of aminoglycosides with magnesium may increase risk of neuromuscular weakness and paralysis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glimepiride",
            "description": {
                "common": "trimagnesium citrate anhydrous increases levels of glimepiride by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glipizide",
            "description": {
                "common": "trimagnesium citrate anhydrous increases levels of glipizide by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "glyburide",
            "description": {
                "common": "trimagnesium citrate anhydrous increases levels of glyburide by enhancing GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "isradipine",
            "description": {
                "common": "trimagnesium citrate anhydrous, isradipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levofloxacin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of levofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "levothyroxine",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of levothyroxine by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "minocycline",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of minocycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "moxifloxacin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of moxifloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nicardipine",
            "description": {
                "common": "trimagnesium citrate anhydrous, nicardipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nisoldipine",
            "description": {
                "common": "trimagnesium citrate anhydrous, nisoldipine.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "nitrofurantoin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of nitrofurantoin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of nitrofurantoin; administer nitrofurantoin at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "ofloxacin",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of ofloxacin by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of quinolones; administer quinolone at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "omadacycline",
            "description": {
                "common": "trimagnesium citrate anhydrous will decrease the level or effect of omadacycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "rilpivirine",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of rilpivirine by increasing gastric pH. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Coadministration of antacids with rilpivirine may cause significant decreases in rilpivirine plasma concentrations because of increased gastric pH. If antacids must be administered, they should given at least 2 hr before or at least 4 hr after rilpivirine."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "sarecycline",
            "description": {
                "common": "trimagnesium citrate anhydrous will decrease the level or effect of sarecycline by  inhibition of GI absorption. Applies only to oral form of both agents. Modify Therapy/Monitor Closely. Multivalent cation-containing products may impair absorption of tetracyclines, which may decrease its efficacy. Separate dosing of tetracyclines from these products."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "streptomycin",
            "description": {
                "common": "streptomycin, trimagnesium citrate anhydrous.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of aminoglycosides with magnesium may increase risk of neuromuscular weakness and paralysis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tetracycline",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of tetracycline by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor. Multivalent cation-containing products may reduce bioavailability of tetracyclines; administer tetracycline at least 2 hr before or 6 hr after magnesium; use alternatives if available."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tiludronate",
            "description": {
                "common": "trimagnesium citrate anhydrous decreases levels of tiludronate by inhibition of GI absorption. Applies only to oral form of both agents. Use Caution/Monitor."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "tobramycin",
            "description": {
                "common": "tobramycin, trimagnesium citrate anhydrous.\nEither increases effects of the other by Other (see comment). Use Caution/Monitor. \nComment: Coadministration of aminoglycosides with magnesium may increase risk of neuromuscular weakness and paralysis."
            }
        },
        {
            "classification_type": "Monitor Closely",
            "interaction_with": "verapamil",
            "description": {
                "common": "trimagnesium citrate anhydrous, verapamil.\nEither increases effects of the other by sedation. Use Caution/Monitor. Possible additive effect of magnesium and calcium channel blockers on reduction of ionic calcium may increase risk of hypotension or muscle weakness."
            }
        }
    ],
    "adverse effects": [
        {
            "name": "Asthenia",
            "percent": null
        },
        {
            "name": "Dizziness",
            "percent": null
        },
        {
            "name": "Hypotension",
            "percent": null
        },
        {
            "name": "Respiratory depression",
            "percent": null
        },
        {
            "name": "Diarrhea",
            "percent": null
        },
        {
            "name": "Abdominal cramping",
            "percent": null
        },
        {
            "name": "Electrolyte imbalance",
            "percent": null
        },
        {
            "name": "Hypermagnesemia",
            "percent": null
        },
        {
            "name": "Muscle weakness",
            "percent": null
        }
    ]
}